Reviewing Bioxytran (OTCMKTS:BIXT) & uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE) and Bioxytran (OTCMKTS:BIXT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares uniQure and Bioxytran”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10 million	105.15	-$198.97 million	($3.48)	-7.71
Bioxytran	N/A	N/A	-$2.12 million	($0.02)	-1.52

Bioxytran has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Bioxytran, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

uniQure has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Bioxytran has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Institutional and Insider Ownership

78.8% of uniQure shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 70.0% of Bioxytran shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares uniQure and Bioxytran’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Bioxytran	N/A	N/A	-737.48%

Analyst Recommendations

This is a summary of recent recommendations and price targets for uniQure and Bioxytran, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1	6	10	0	2.53
Bioxytran	0	0	0	0	0.00

uniQure presently has a consensus price target of $42.83, indicating a potential upside of 59.57%. Given uniQure’s stronger consensus rating and higher possible upside, equities analysts plainly believe uniQure is more favorable than Bioxytran.

Summary

Bioxytran beats uniQure on 7 of the 13 factors compared between the two stocks.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.